Isu Abxis Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.51, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.25, suggesting limited short-term liquidity cushion. The company's price-to-book ratio is 2.44, and its price-to-tangible-book ratio is also 2.44, indicating that the market values the company at a premium to its book value. However, the company's enterprise value to EBITDA ratio is negative at -12.73, reflecting its current unprofitability.

Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of KRW 16,378,928,680 and an operating loss of KRW 12,712,366,330, resulting in a negative return on equity of -26.49% and a negative return on assets of -11.76%. These figures are well below the typical profitability thresholds for the pharmaceuticals industry, which usually expects positive ROE and ROA figures.

Geographically, the company's revenue is concentrated in South Korea, with no disclosed international revenue segments. The company operates in a single business segment focused on diagnostic products and services. This lack of diversification increases exposure to local market conditions and regulatory changes.

The company's growth trajectory is mixed. While revenue for the latest period was KRW 16,510,899,950, the company is currently operating at a loss. The outlook for the current fiscal year is negative, with no disclosed revenue growth expected. The company's operating cash flow is negative at KRW -6,403,195,720, and its free cash flow is also negative at KRW -17,915,480,160, indicating a lack of cash generation.

Risk factors include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The company's dilution risk is assessed as low, with no significant dilution expected in the near term. The company has not disclosed any recent share issuance or dilutive events, and its diluted shares outstanding are equal to its basic shares outstanding.

Recent events include the company's latest financial filing, which disclosed a significant operating and net loss. The company has not issued any recent earnings transcripts or press releases that would indicate a change in strategic direction or product development. The company's capital expenditure of KRW -2,606,651,530 suggests a reduction in investment in physical assets.

FY-1 revenue reached 60.3 billion KRW, representing the highest top-line performance in the available four-year historical dataset.

FY-1 net income surged to 14.7 billion KRW, marking a significant profitability peak compared to recent fiscal periods.

Long-term debt decreased to 29.2 billion KRW in FY-1, down from 65.1 billion KRW in FY-2, indicating deleveraging efforts.

Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value from share issuance.

Operating income collapsed to -7.5 billion KRW in FY-1, reflecting a severe deterioration in core operational profitability.

Credit risk is flagged as high, indicating substantial concerns regarding the company's ability to meet its financial obligations.

Revenue KRW 20.64B; Operating income KRW 2.02B.

• ▍Revenue KRW 20.64B
• ▍Operating income KRW 2.02B
• ▍Net margin 135.3%

Revenue KRW 8.76B; Operating income -KRW 439.9M.

• ▍Revenue KRW 8.76B
• ▍Operating income -KRW 439.9M
• ▍Net margin 12.8%

Revenue KRW 14.34B; Operating income KRW 3.62B.

• ▍Revenue KRW 14.34B
• ▍Operating income KRW 3.62B
• ▍Net margin 14.3%

Revenue KRW 16.51B; Operating income -KRW 12.71B.

• ▍Revenue KRW 16.51B
• ▍Operating income -KRW 12.71B
• ▍Net margin -99.2%

Revenue KRW 60.26B, +11,0% YoY; Operating income −293,4% YoY.

• ▍Revenue KRW 60.26B, +11,0% YoY
• ▍Operating income −293,4% YoY
• ▍Net income +307,6% YoY
• ▍Free cash flow +525,1% YoY
• ▍Net margin 24.4%